IMR Press / CEOG / Special Issues / smooth_muscle_uterine_tumors

Smooth Muscle Uterine Tumors: An Update

Submission deadline: 30 September 2022
Special Issue Editors
Special Issue Information

Dear Colleagues,

Smooth muscles are found in the hollow organs of the body, including the bowel, stomach, bladder, and blood vessels, as well as the uterus in women. Smooth muscle uterine tumors (SMUTs) are the most frequent mesenchymal uterine tumors and are classified as benign or malignant based on their microscopic appearance and immunohistochemistry. SMUTs range from benign leiomyomas to low- and high-grade leiomyosarcomas (LMSs) and are classified according to their morphologic features, including architecture, growth pattern, cellular characteristics and constituents of the intercellular stroma. The benign forms are widespread in the female population and cause many health problems with negative consequences on the well-being of patients and on reproduction. Occasionally, the differential diagnosis with a LMS can become challenging when unusual features are detected in some benign variants. Diagnostic criteria for the different subtypes of LMS are not uniform and hence it is often necessary to resort to immunohistochemical techniques. SMUTs may also show overlapping histologic and even immunohistochemical features, thus further complicating their correct classification. This issue includes an update on uterine smooth muscle tumor of uncertain malignant potential (STUMP), intravenous leiomyomatosis, benign metastasizing leiomyoma, and diffuse leiomyomatosis. Generally, it is probably more useful to classify SMUTs as tumors either with or without recurrent and/or metastatic potential. Benign tumors with a low risk of recurrence but atypical histologic features are also called "atypical leiomyoma". These are variously known as leiomyoma with bizarre nuclei, symplastic leiomyoma, or pleomorphic leiomyoma. Other variants of benign SMUTs are mitotically active leiomyoma, cellular and highly cellular leiomyoma, epithelioid leiomyoma, and myxoid leiomyoma. However, challenges can arise when dealing with malignant forms. These are generally very aggressive and have bad prognosis, such as with uterine LMS. This is a soft tissue aggressive sarcoma type responsible for 10–20% of all soft tissue sarcoma cases, albeit with a rare incidence in the total female population. The diagnosis of malignant SMUTs has important prognostic and therapeutic implications. In this issue, the authors will provide an overview of SMUTs and their impact on women in light of recent scientific advances.

Dr. Andrea Tinelli and Dr. Vincenzo Emanuele Chiuri

Guest Editors

smooth uterine muscle of uncertain malignant potential
Smooth Muscle Uterine Tumors
uterine mass
myometrial tissue
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Back to top